Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project

Fiona H. Blackhall, Solange Peters, Lukas Bubendorf, Urania Dafni, Keith M. Kerr, Henrik Hager, Alex Soltermann, Kenneth J. O'Byrne, Christoph Dooms, Aleksandra Sejda, Javier Hernandez-Losa, Antonio Marchetti, Spasenija Savic, Qiang Tan, Erik Thunnissen, Ernst-Jan M. Speel, Richard Cheney, Daisuke Nonaka, Jeroen de Jong, Miguel MartorellIgor Letovanec, Rafael Rosell, Rolf A. Stahel

Research output: Contribution to journalArticleAcademicpeer-review

50 Citations (Scopus)
Original languageEnglish
Pages (from-to)2780-+
JournalJournal of Clinical Oncology
Volume32
Issue number25
DOIs
Publication statusPublished - 1 Sep 2014

Cite this

Blackhall, F. H., Peters, S., Bubendorf, L., Dafni, U., Kerr, K. M., Hager, H., Soltermann, A., O'Byrne, K. J., Dooms, C., Sejda, A., Hernandez-Losa, J., Marchetti, A., Savic, S., Tan, Q., Thunnissen, E., Speel, E-J. M., Cheney, R., Nonaka, D., de Jong, J., ... Stahel, R. A. (2014). Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 32(25), 2780-+. https://doi.org/10.1200/JCO.2013.54.5921